Waters Gears Up to Report Q3 Results: How to Play the Stock?

WAT's Q3 results are likely to benefit from strong revenue growth prospects, rising demand and acquisition gains.

Zacks Investment Research • Oct 28, 2026

Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software

Advances Waters' strategy to bring trusted AI, ML, and automation capabilities to the 500,000 Empower™ Software users who run the world's regulated chromatography labs and support the release of over 80% of medicines globally AI-Powered Peak Integration transforms chromatography data processing in regulated environments, using AI to reduce manual interventions by up to 95% while delivering 76% greater accuracy and a 72% reduction in user-to-user variability Joins a growing portfolio of premium AI capabilities Waters is building directly into Empower Software, uniquely enabling AI, ML, and automation inside the validated environment where highly protected customer data resides, with no compromise to integrity, traceability, or compliance MILFORD, Mass., Oct. 28, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced AI-Powered Peak Integration, the next step in its strategy to build intelligent AI, machine learning, and automation cloud-based capabilities directly into Empower Software, the chromatography data system of record for regulated laboratories worldwide.

PRNewsWire • Oct 28, 2026

Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests

WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer screening.

Zacks Investment Research • Oct 27, 2026

First Eagle U.S. Value Fund Q3 2026 Portfolio Review

U.S. Fund A Shares (without sales charge) posted a return of 4.36% in third-quarter 2026. The US Fund outperformed the S&P 500 Index in the period. Shares of Meta performed well following the strong reception of Muse, its personalized AI assistance app.

Seeking Alpha • Oct 26, 2026

Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026

Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, patient service center, and at-home settings Through a network serving more than 850,000 physicians and healthcare providers and more than 2,200 patient service centers, Labcorp is helping expand access to cervical cancer screening nationwide First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping MILFORD, Mass. and BURLINGTON, N.C.

PRNewsWire • Oct 23, 2026

Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027 First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping Quest Diagnostics serves half of U.S. physicians and hospitals and one in three American adults each year MILFORD, Mass. and SECAUCUS, N.J.

PRNewsWire • Oct 20, 2026

Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows

WAT's AI Link launch and Anthropic collaboration aim to automate LC-MS workflows, streamline lab operations and drive instrument demand.

Zacks Investment Research • Oct 20, 2026

Two stocks poised to benefit from rotation out of AI

Investors looking beyond artificial intelligence (AI) should closely watch two healthcare names – Thermo Fisher Scientific (TMO) and Waters (WAT) – according to Josh Brown. In his latest report, the Ritholtz' chief executive highlighted laboratory equipment suppliers whose improving businesses are attracting buyers as tech stocks face pressure.

Invezz • Oct 19, 2026

Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release

Accelerates research and development by enabling AI-augmented workflows and automated lab-in-the-loop cycles, already a new and fast-growing source of demand for Waters' instruments and consumables Leverages Waters' unique ability to take an AI-directed experiment from the research bench into development and into Empower™ Software, carrying its audit trail as the molecule moves into downstream, regulated settings Joins Anthropic's Model Hardware Standard (MHS) research program designed to enable AI agents to operate Waters instrument hardware directly and autonomously, cutting instrument integration from weeks to hours Brings Anthropic's Model Context Protocol (MCP) to waters_connect™ Software, enabling scientists to direct Waters instruments through proprietary agents linked to large language models (LLMs), as well as Claude Science MILFORD, Mass., Oct. 13, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that it has launched Waters AI Link, a software capability that brings Anthropic's Model Context Protocol (MCP) to its informatics platform and has joined Anthropic's Model Hardware Standard (MHS) research program.

PRNewsWire • Oct 13, 2026

Here's Why You Should Retain WAT Stock in Your Portfolio for Now

Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.

Zacks Investment Research • Oct 8, 2026